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Abstract: Transforming growth factor-beta (TGFβ) signaling in cancer is context dependent and acts either as a tu-
mor suppressor or a tumor promoter. Loss of function mutation in TGFβ type II receptor (TβRII) is a frequent event 
in oral cavity squamous cell carcinoma (SCC). Recently, heterogeneity of TGFβ response has been described at the 
leading edge of SCC and this heterogeneity has been shown to influence stem cell renewal and drug resistance. Be-
cause exosome transfer from stromal to breast cancer cells regulates therapy resistance pathways we investigated 
whether exosomes contain components of the TGFβ signaling pathway and whether exosome transfer between 
stromal fibroblasts and tumor cells can influence TGFβ signaling in SCC. We demonstrate that exosomes purified 
from stromal fibroblasts isolated from patients with oral SCC contains TβRII. We also demonstrate that transfer of 
fibroblast exosomes increases TGFβ signaling in SCC keratinocytes devoid of TβRII which remain non-responsive to 
TGFβ ligand in the absence of exosome transfer. Overall our data show that stromal communication with tumor cells 
can direct TGFβ signaling in SCC.
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Introduction
Squamous cell carcinoma (SCC) arises in tis-
sues that provide a barrier between an organ-
ism and the environment, such as the skin, oral 
cavity, esophagus and lung. SCC comprises 
over 90% of cancers of the head and neck and 
can occur in skin and the squamous lining of 
the mucosal surfaces of the upper aerodiges-
tive tract, including the oral cavity, pharynx, lar-
ynx, and sinonasal tract [1]. Head and neck 
SCC (HNSCC) is the sixth most common cancer 
in the world, and it is anticipated that over 
52,000 people are diagnosed in US each year 
[2, 3]. Despite new therapies and improved risk 
stratification, overall survival in subjects with 
HNSCC is poor and only 50-60% of patients 
diagnosed with HNSCC are alive after 5 years 
[4, 5]. Thus, HNSCC is a major clinical pro- 
blem.
Transforming growth factor-beta (TGFβ) recep-
tors participate in a signaling pathway that con-
trols many aspects of mammalian development 
and tissue homeostasis [6]. The so called 
canonical TGFβ signaling pathway begins with 
binding of ligand (TGFβ1-3) to the type II recep-
tor (TβRII) which in turn recruits the type I recep-
tor (TβRI) leading to transphosphorylation of 
the resulting heterotetramer. This activated 
complex then recruits SMAD2 and SMAD3 
which are themselves phosphorylated, leading 
to nuclear translocation and subsequent gene 
expression [7].
The role of TGFβ in SCC is controversial [8]; in 
murine studies of skin SCC a paradox emerges 
whereby TGFβ expression in the epidermis 
inhibits papilloma formation yet accelerates 
malignant conversion [9]. Furthermore, condi-
tional ablation of TβRII induces cancer raising 
important questions about the timing and 
response to TGFβ signaling in tumor develop-
ment [10, 11]. In humans, mutation in TβRI 
leads to Ferguson-Smith syndrome, a familial 
disorder characterized by multiple, regressing 
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SCC or keratoacanthomas of the skin [12]. 
Mutations in TβRI have also been identified in 
rapidly arising keratoacanthomas and skin SCC 
in patients receiving the broad kinase inhibitor 
sorafenib [13] and patients receiving the anti-
TGFβ antibody, fresolimumab also frequently 
develop keratoacanthomas and SCC [14]. 
Moreover, The Cancer Genome Atlas Network 
identified sporadic inactivating mutations and 
deletions in the gene encoding TβRII in HNSCC, 
primarily oral cavity tumors [15]. Collectively 
these human clinical observations support the 
notion that inactivation of TGFβ leads to SCC 
initiation and yet TGFβ remains an important 
signaling pathway for cancer progression [8, 9]. 
Recently it has been shown that response to 
TGFβ at the tumor stroma interface contributes 
to SCC progression and drug resistance [16] 
raising the possibility that TGFβ signaling might 
be influenced by intercellular communication 
between tumor and the microenvironment, a 
mechanism shown to promote therapy resis-
tance in other cancers [17]. Local or systemic 
cell-cell communications have been shown to 
be mediated by transfer of DNA, microRNA, 
mRNA, lipids and proteins via exosomes, which 
are 30-150 nm vesicles derived from the intra-
luminal membrane budding of multivesicular 
bodies [18, 19]. These vesicles are defined by 
enrichment of specific lipid-raft proteins, such 
as tetraspanins (CD9, CD63, CD81) and flotil-
lin-1 (FLOT1) [20, 21-24]. Two general mecha-
nisms have been hypothesized to explain the 
transfer of exosomal content between cells; 
both mechanisms propose that exosomes 
incorporate transmembrane proteins into the 
plasma membrane of the recipient cell and 
release their lumen content into the cytoplasm 
[25, 26].
In this study we show that exosomes isolated 
from stromal fibroblasts contain components 
of the TGFβ signaling pathway and that exo-
some transfer between stromal fibroblasts and 




Ethical approval for this investigation (#15D. 
548) was obtained from the Jefferson Institu- 
tional Review Board. All patients participating 
in this study provided written, informed con-
sent. Primary keratinocytes and fibroblasts 
were isolated from fresh tissue obtained from 
patients undergoing SCC surgery, and cultured 
in media containing serum and, for keratino-
cytes only, supplemented with growth factors 
as previously described [27].
Antibodies
The antibodies used in this study were: P-SM- 
AD2 rabbit monoclonal (Ser465/467 138D4 
#3108, Cell Signaling Technology, Danvers, 
MA); P-SMAD3 rabbit monoclonal (Ser423/425 
EP823Y ab52903, Abcam, Cambridge, MA); 
total-SMAD2/3 rabbit polyclonal (#3102, Cell 
Signaling Technology); GAPDH mouse monoclo-
nal (G8795, Sigma Aldrich, St. Louis, MO); TβRII 
(L-21) rabbit polyclonal (sc-400, Santa Cruz 
Biotechnology Inc., Dallas, TX); TSG101 rabbit 
monoclonal (ab-125011, Abcam); CD9 mouse 
monoclonal (sc-13118, Santa Cruz Biotechno- 
logy, Inc.), calnexin (H-70) rabbit polyclonal (sc-
11397, Santa-Cruz Biotechnology, Inc.).
Exosome isolation and characterization
Cells were washed with PBS and grown in 
serum-free medium for 48 h and exosomes 
were isolated as described [20, 28, 29].
Exosome uptake
SCC keratinocytes were serum starved for 24 h 
and then incubated with 20 or 30 µg/mL of 
fibroblasts exosomes. After 24 h, cells were 
washed twice with PBS and incubated with 
TGFβ1 (5 ng/mL dilution from 100 mg/mL 
stock dissolved in 20 mM Sodium Citrate pH 
3.0; Cell signaling Technology) for 30 min at 
37°C. Cells were then washed again and lysed 
using RIPA buffer. Protein quantification was 
performed using the BCA protein assay kit. 
P-SMAD3, P-SMAD2, Total SMAD2/3, TβRII 
expression was analyzed using immunoblot-
ting. GAPDH was used as a loading control.
Immunoblotting
Whole cell extracts and exosome lysates were 
collected using RIPA buffer and protein concen-
tration determined by BCA protein assay kit 
(Thermo Fisher Scientific). Proteins were sepa-
rated by electrophoresis using 10% SDS/PAGE 
gels. Proteins were transferred to a nitrocellu-
lose membrane using the Trans-Blot® Turbo™ 
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system (Bio-Rad, Hercules, CA). For exosome 
characterization, equal amounts of total cell 
lysates and exosome lysates were resolved 
using 12.5% SDS/PAGE gels. Proteins were 
transferred to a PVDF membrane and analysis 
was performed as described before [29].
Results
Primary SCC fibroblasts respond to TGFβ 
Primary keratinocytes cultured from SCC pa- 
tient specimens exhibited variation in TGFβ 
response. Of the 14 populations of SCC kerati-
nocytes tested, 3 were unresponsive to TGFβ1 
stimulation, one of which did not express 
detectable levels of TβRII (Figure 1 and data 
not shown). In contrast 12/12 primary fibro-
blast populations cultured from SCC patient 
resected tissue robustly signaled after TGFβ1 
stimulation, as determined by phospho-specific 
antibodies against SMAD2 and SMAD3 (Figure 
1 and data not shown). 
TβRII is present in exosomes isolated from 
SCC fibroblasts
We analyzed components of the TGFβ signaling 
pathway in exosomes isolated from SCC fibro-
blasts. In each case we demonstrated that the 
TGFβ receptor, TβRII was present in exosomes 
(Figure 2), whereas we did not detect the pres-
ence of SMAD2 or SMAD3 in exosomes isolat-
ed from SCC fibroblasts (data not shown).
Exosome transfer from fibroblasts increases 
TGFβ signaling in SCC keratinocytes
Next, we investigated whether exosome trans-
fer from TGFβ signaling-competent fibroblasts 
was able to confer TGFβ signaling to SCC kera-
tinocytes deficient in TGFβ ligand response. We 
demonstrated that exosome transfer increased 
TBRII levels and SMAD2 phosphorylation in 
SCC keratinocytes (Figure 3) while SMAD3 
phosphorylation did not consistently change 
(data not shown). An increase in P-SMAD2 was 
observed in four separate transfer experiments 
using either a pool of exosome preparations or 
exosomes isolated from a single fibroblast pop-
ulation. Furthermore, stimulation of SCC kerati-
nocytes with recombinant TGFβ1 after exo-
some transfer resulted in a small, but further 
increase of phosphorylated SMAD2 (Figure 3).
Discussion
Here we show that TβRII is present in exosomes 
isolated from fibroblasts and that TβRII can be 
transferred to SCC keratinocytes via exosomes. 
We further show that exosome transfer incr- 
eased TGFβ signaling, as determined by phos-
Figure 1. Lack of TβRII in SCC tumor keratinocytes 
abrogates SMAD phosphorylation response to TGFβ 
ligand. Of 14 populations of keratinocytes cultured 
from SCC patient resected tissue, 3 were unrespon-
sive to TGFβ1 stimulation (5 ng/ml for 30 min), one 
of which did not express detectable levels of TβRII 
(SCCK, shown here). 12/12 fibroblast populations 
cultured from SCC patient resected tissue robustly 
signaled via SMAD phosphorylation (P-SMAD) after 
TGFβ1 stimulation. Examples of fibroblast popula-
tions, HN3 and HN4, are shown (HN3F and HN4F).
Figure 2. TβRII is expressed in exosomes released 
from fibroblasts. Exosomes were purified via ultra-
centrifugation from fibroblast culture media (HN3F 
and HN4F shown). 15 µg of exosome lysates (Ex) and 
total cells lysates (TCL) were loaded on a 12.5% SDS-
PAGE gel. Immunoblotting analysis shows that TβRII 
is expressed in exosomes. Each exosome prepara-
tion was characterized by detection of TSG101 and 
CD9, markers that are enriched in exosomes com-
pared to cell lysates. Calnexin, an endoplasmic re-
ticulum protein is not detected in exosomes.
Exosome-mediated transfer of TβRII
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phorylation of SMAD2, and that stimulation of 
SCC keratinocytes with recombinant TGFβ1 
after exosome transfer further increased phos-
phorylation of SMAD2, albeit only slightly.
Previous work by others has shown that cancer 
derived exosomes can increase TGFβ signaling 
in mesenchymal cells. Specifically, exosomes 
isolated from gastric, breast and ovarian carci-
noma cell lines convert mesenchymal stem 
cells (derived from either adipocytes or umbili-
cal cord) to a myofibroblast lineage determined 
by alpha smooth muscle actin expression and 
increased phosphorylation of SMAD2 [30-32]. 
No components of the TGFβ signaling pathway 
were reported to be present in cancer derived 
exosomes in these prior studies. To our knowl-
edge our study is the first to demonstrate that 
TβRII is present in exosomes isolated from the 
tumor microenvironment, that TβRII can be 
transferred via exosomes, and that exosomal 
transfer can stimulate TGFβ signaling in tumor 
cells that are unresponsive to TGFβ ligand in 
the absence of exosomal transfer.
Based on our data we find the most likely expla-
nation for increased TGFβ signaling after exo-
some transfer is TβRII transfer. Increased phos-
phorylated SMAD2 after exosome transfer 
alone is likely due to secretion of TGFβ ligand 
from the SCC keratinocytes thereby stimulating 
transferred TβRII. However, we cannot rule out 
the possibility that SMAD2 phosphorylation is a 
result of non-canonical TGFβ signaling after 
transfer of components other than SMAD2 or 
SMAD3 proteins, including micro-RNAs, pres-
ent in fibroblast exosomes that we have yet to 
identify. Indeed, in the experiment shown in 
Figure 3 there is an observed increase, albeit 
small, in total SMAD2/3 levels which may be a 
result of exosome transfer. Regardless of these 
details the fact remains that TGFβ signaling can 
be stimulated in SCC tumor cells via exosome 
transfer from the tumor microenvironment.
It has been shown that membrane trafficking 
can regulate TβRII activity and degradation, 
and that sorting of TβRII into the early endo-
some is important for SMAD complex formation 
[33]. Further work is necessary to determine 
the precise nature of how exosome transfer 
regulates TGFβ signaling in SCC and whether 
TGFβ signaling itself can influence exosome 
secretion.
The paradox presented by TGFβ signaling in 
SCC, whereby loss of function results in tumor 
initiation and increased signaling promotes 
progression [9], cannot be explained solely by 
genetics, as loss of function mutation would 
preclude subsequent signaling. Our data 
address such a paradox and provide a mecha-
nism for SCC heterogeneity in response to 
TGFβ, particularly at the leading edge of invad-
ing tumors where communication between the 
microenvironment is most likely [34]. In sum-
mary, we present a potent mechanism, exo-
somal transfer from the tumor microenviron-
ment, for re-activation of TGFβ signaling in SCC 
tumors that have lost the response to TGFβ 
ligand.
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Figure 3. Exosomal transfer increases phosphoryla-
tion of SMAD2 and levels of TβRII in SCC tumor ke-
ratinocytes. Exosomes (Ex) were isolated and pooled 
from 4 separate populations of fibroblasts derived 
from patients with SCC. SCC keratinocytes were se-
rum starved for 24 h and then incubated with 20 µg/
mL of fibroblast exosomes (Ex +) or PBS without exo-
somes (Ex -). After 24 h, cells were washed twice with 
PBS and incubated with (TGFβ +) or without (TGFβ 
-) TGFβ1 (5 ng/mL) for 30 min at 37°C. Cells were 
then washed again and lysed using RIPA buffer. Im-
munoblotting was performed using antibodies to 
phosphorylated SMAD2, SMAD2/3, TβRII or GAPDH.
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